Analyst firms · Morgan Stanley · RMD

Morgan Stanley RMD price target and rating history

ResMed Inc. (RMD) · Health Care

Morgan Stanley rates ResMed Inc. (RMD) Equal-Weight with a $230 price target, as of its latest action on Jun 17, 2026. It has published 4 rating actions on RMD since October 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Morgan Stanley's $230 is 2% below that.

Current rating
Equal-Weight
Price target
$230
Median target, all firms
$235
Actions on RMD
4

Morgan Stanley price target on RMD

$280$225$169202420252026
Morgan Stanley price target on RMD, each point a stated target, October 2023 to June 2026.

Every Morgan Stanley rating on RMD

How other firms rate RMD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Canaccord GenuityHoldNov 2, 2026
RBC Capital MarketsOutperform$262Sep 15, 2026
Rothschild & Co RedburnNeutral$230Aug 19, 2026
CitigroupNeutral$235Jul 13, 2026
Morgan StanleyEqual-Weight$230Jun 17, 2026
Robert W. BairdNeutral$275Dec 16, 2025

Questions about Morgan Stanley and RMD

What is Morgan Stanley's price target for RMD?
Morgan Stanley's latest stated price target for ResMed Inc. (RMD) is $230, from its action on Jun 17, 2026.
What is Morgan Stanley's rating on RMD?
Morgan Stanley rates RMD Equal-Weight, a neutral rating, as of Jun 17, 2026.
When did Morgan Stanley last change its view on RMD?
On Jun 17, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $230.
How does Morgan Stanley's RMD target compare with other analysts?
Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Morgan Stanley's $230 is 2% below that.

More RMD rating histories

All Morgan Stanley ratingsRMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.